Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Anker

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
The New England Journal of Medicine|September 16, 2020
Liraglutide for Adolescents with ObesityMarkus S Anker, Javed Butler, Stefan D Anker
Journal of Cachexia, Sarcopenia and Muscle|December 19, 2020
Blocking myostatin: muscle mass equals muscle strength?Markus S Anker, Stephan von Haehling, Jochen Springer
Der Internist|October 14, 2020
[Tumor effects on the heart and circulation]M S Anker, S Hadzibegovic, S von Haehling
European Heart Journal|January 30, 2026
The EMPATICC-trial-should location shape therapy?Markus S Anker, Stefan D Anker, Tienush Rassaf
The New England Journal of Medicine|November 9, 2018
A Phase 3 Trial of l-Glutamine in Sickle Cell DiseaseMarkus S Anker, Wilhelm Haverkamp, Stefan D Anker
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 27, 2016
Advances in cachexia and sarcopenia research in the heart failure context: call for actionJochen Springer, Markus S Anker, Stefan D Anker
Journal of the American College of Cardiology|July 5, 2023
Understanding Who Responds to M-TEER in Heart Failure With SMR: Malnutrition Does Not Preclude BenefitMarkus S Anker, Stephan von Haehling, Ulf Landmesser
The New England Journal of Medicine|December 4, 2023
Ferric Carboxymaltose in Heart Failure with Iron DeficiencyStefan D Anker, Gerasimos Filippatos, Markus S Anker
The New England Journal of Medicine|April 15, 2026
Cardiovascular Outcomes with Tirzepatide in Type 2 DiabetesMarkus S Anker, Javed Butler, Stefan D Anker
Analytical Chemistry|December 15, 1990
Quantitative structure-retention relationship studies of odor-active aliphatic compounds with oxygen-containing functional groupsL S Anker, P C Jurs, P A Edwards
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
The New England Journal of Medicine|September 16, 2020
Liraglutide for Adolescents with ObesityMarkus S Anker, Javed Butler, Stefan D Anker
Journal of Cachexia, Sarcopenia and Muscle|December 19, 2020
Blocking myostatin: muscle mass equals muscle strength?Markus S Anker, Stephan von Haehling, Jochen Springer
Der Internist|October 14, 2020
[Tumor effects on the heart and circulation]M S Anker, S Hadzibegovic, S von Haehling
European Heart Journal|January 30, 2026
The EMPATICC-trial-should location shape therapy?Markus S Anker, Stefan D Anker, Tienush Rassaf
The New England Journal of Medicine|November 9, 2018
A Phase 3 Trial of l-Glutamine in Sickle Cell DiseaseMarkus S Anker, Wilhelm Haverkamp, Stefan D Anker
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 27, 2016
Advances in cachexia and sarcopenia research in the heart failure context: call for actionJochen Springer, Markus S Anker, Stefan D Anker
Journal of the American College of Cardiology|July 5, 2023
Understanding Who Responds to M-TEER in Heart Failure With SMR: Malnutrition Does Not Preclude BenefitMarkus S Anker, Stephan von Haehling, Ulf Landmesser
The New England Journal of Medicine|December 4, 2023
Ferric Carboxymaltose in Heart Failure with Iron DeficiencyStefan D Anker, Gerasimos Filippatos, Markus S Anker
The New England Journal of Medicine|April 15, 2026
Cardiovascular Outcomes with Tirzepatide in Type 2 DiabetesMarkus S Anker, Javed Butler, Stefan D Anker
Analytical Chemistry|December 15, 1990
Quantitative structure-retention relationship studies of odor-active aliphatic compounds with oxygen-containing functional groupsL S Anker, P C Jurs, P A Edwards
Pageof 19